333 related articles for article (PubMed ID: 25251475)
1. Eravacycline for the treatment of intra-abdominal infections.
Bassetti M; Righi E
Expert Opin Investig Drugs; 2014 Nov; 23(11):1575-84. PubMed ID: 25251475
[TBL] [Abstract][Full Text] [Related]
2. Eravacycline, a newly approved fluorocycline.
Lee YR; Burton CE
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1787-1794. PubMed ID: 31175478
[TBL] [Abstract][Full Text] [Related]
3. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.
Solomkin J; Evans D; Slepavicius A; Lee P; Marsh A; Tsai L; Sutcliffe JA; Horn P
JAMA Surg; 2017 Mar; 152(3):224-232. PubMed ID: 27851857
[TBL] [Abstract][Full Text] [Related]
4. Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance.
Solomkin JS; Sway A; Lawrence K; Olesky M; Izmailyan S; Tsai L
Future Microbiol; 2019 Oct; 14():1293-1308. PubMed ID: 31570004
[No Abstract] [Full Text] [Related]
5. Eravacycline for the treatment of complicated intra-abdominal infections.
Montravers P; Zappella N; Tran-Dinh A
Expert Rev Anti Infect Ther; 2019 Nov; 17(11):851-863. PubMed ID: 31622119
[No Abstract] [Full Text] [Related]
6. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections.
Solomkin JS; Gardovskis J; Lawrence K; Montravers P; Sway A; Evans D; Tsai L
Clin Infect Dis; 2019 Aug; 69(6):921-929. PubMed ID: 30561562
[TBL] [Abstract][Full Text] [Related]
7. Eravacycline for the treatment of patients with bacterial infections.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2018 Apr; 54(4):245-254. PubMed ID: 29869646
[TBL] [Abstract][Full Text] [Related]
8. Eravacycline: A Review in Complicated Intra-Abdominal Infections.
Scott LJ
Drugs; 2019 Feb; 79(3):315-324. PubMed ID: 30783960
[TBL] [Abstract][Full Text] [Related]
9. Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications.
Huang PY; Hsu CK; Tang HJ; Lai CC
Expert Rev Anti Infect Ther; 2024 Jun; 22(6):387-398. PubMed ID: 38703093
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.
Lin SY; Huang CH; Ko WC; Chen YH; Hsueh PR
Expert Opin Pharmacother; 2016; 17(3):339-54. PubMed ID: 26610040
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015.
Zhanel GG; Baxter MR; Adam HJ; Sutcliffe J; Karlowsky JA
Diagn Microbiol Infect Dis; 2018 May; 91(1):55-62. PubMed ID: 29338931
[TBL] [Abstract][Full Text] [Related]
12. Eravacycline (Xerava)--an IV tetracycline for complicated intra-abdominal infections.
Med Lett Drugs Ther; 2019 Apr; 61(1570):61-63. PubMed ID: 31169809
[No Abstract] [Full Text] [Related]
13. In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.
Zhang Y; Lin X; Bush K
J Antibiot (Tokyo); 2016 Aug; 69(8):600-4. PubMed ID: 27353166
[TBL] [Abstract][Full Text] [Related]
14. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections.
Solomkin JS; Ramesh MK; Cesnauskas G; Novikovs N; Stefanova P; Sutcliffe JA; Walpole SM; Horn PT
Antimicrob Agents Chemother; 2014; 58(4):1847-54. PubMed ID: 24342651
[TBL] [Abstract][Full Text] [Related]
15. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance.
Syue LS; Chen YH; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2016 Apr; 47(4):250-8. PubMed ID: 27005457
[TBL] [Abstract][Full Text] [Related]
16. Eravacycline: The Tetracyclines Strike Back.
Heaney M; Mahoney MV; Gallagher JC
Ann Pharmacother; 2019 Nov; 53(11):1124-1135. PubMed ID: 31081341
[No Abstract] [Full Text] [Related]
17. Delafloxacin for the treatment of respiratory and skin infections.
Bassetti M; Della Siega P; Pecori D; Scarparo C; Righi E
Expert Opin Investig Drugs; 2015 Mar; 24(3):433-42. PubMed ID: 25604710
[TBL] [Abstract][Full Text] [Related]
18. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
Nicolau DP
Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
[TBL] [Abstract][Full Text] [Related]
19. Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
Bassetti M; Righi E
Future Microbiol; 2015; 10(2):151-60. PubMed ID: 25689527
[TBL] [Abstract][Full Text] [Related]
20. Tigecycline: an update.
Stein GE; Babinchak T
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
